FDA expands use of AZ/Merck’s Lynparza in the US

18th August 2017 Uncategorised 0

AstraZeneca and Merck & Co’s Lynparza will be available to a wider range of patients in the US after regulators expanded the PARP inhibitor’s list of approved uses.

More: FDA expands use of AZ/Merck’s Lynparza in the US
Source: News